These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 30401437)

  • 1. Amyotrophic Lateral Sclerosis: An Update for 2018.
    Oskarsson B; Gendron TF; Staff NP
    Mayo Clin Proc; 2018 Nov; 93(11):1617-1628. PubMed ID: 30401437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
    Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
    Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying treatment of amyotrophic lateral sclerosis.
    Schultz J
    Am J Manag Care; 2018 Aug; 24(15 Suppl):S327-S335. PubMed ID: 30207671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyotrophic lateral sclerosis: clinical management and research update.
    Andrews J
    Curr Neurol Neurosci Rep; 2009 Jan; 9(1):59-68. PubMed ID: 19080755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic investigation and multidisciplinary management in motor neuron disease.
    Rocha JA; Reis C; Simões F; Fonseca J; Mendes Ribeiro J
    J Neurol; 2005 Dec; 252(12):1435-47. PubMed ID: 16362828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y; Shibuya K; Vucic S; Kiernan MC
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
    Johnson SA; Fang T; De Marchi F; Neel D; Van Weehaeghe D; Berry JD; Paganoni S
    Drugs; 2022 Sep; 82(13):1367-1388. PubMed ID: 36121612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
    Dash RP; Babu RJ; Srinivas NR
    Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.
    Sever B; Ciftci H; DeMirci H; Sever H; Ocak F; Yulug B; Tateishi H; Tateishi T; Otsuka M; Fujita M; Başak AN
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management.
    Gordon PH
    CNS Drugs; 2011 Jan; 25(1):1-15. PubMed ID: 21128691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying therapies in amyotrophic lateral sclerosis.
    Chiò A; Mazzini L; Mora G
    Neuropharmacology; 2020 May; 167():107986. PubMed ID: 32062193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing care of patients with ALS. Steps to early detection and improved quality of life.
    Mackin GA
    Postgrad Med; 1999 Apr; 105(4):143-6, 151-6. PubMed ID: 10223093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
    Cheah BC; Vucic S; Krishnan AV; Kiernan MC
    Curr Med Chem; 2010; 17(18):1942-199. PubMed ID: 20377511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis.
    Morren JA; Galvez-Jimenez N
    Expert Opin Investig Drugs; 2012 Mar; 21(3):297-320. PubMed ID: 22303913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies.
    Vucic S; Rothstein JD; Kiernan MC
    Trends Neurosci; 2014 Aug; 37(8):433-42. PubMed ID: 24927875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.